Compare Biogen Inc (BIIB) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? Biogen Inc trades at $195.62 (market cap $28.34B), while iShares Core MSCI Emerging Markets ETF trades at $78.74. Which is the better fit depends on your goals.
| BIIB | IEMG | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $86.00 |
52-Week Low | $122.68 | $59.90 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
IEMG is trading at $78.49, down 3.49% over the past 24 hours amid a bearish technical signal. The ETF has delivered strong performance with a 35% surge over the past year, driven by its 40% technology weighting and exposure to South Korean and Taiwanese semiconductor stocks. Recent news highlights record inflows into emerging markets and IEMG's cost advantage over competitors like EEM with its 0.09% expense ratio.
The outlook for IEMG remains mixed with attractive emerging market valuations and AI-driven growth potential balanced against elevated volatility and geopolitical risks. While the fund offers diversified exposure to fast-growing economies, investors face concentration risks in tech stocks and potential headwinds from US-China trade tensions that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
